Acute relief or future prevention: Is urology ready for preventive health care?

Urology

Volumn 56, Issue 5 SUPPL. 1, 2000, Pages 12-19

  Roehrborn, Claus G ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CITRATE POTASSIUM; CITRATE POTASSIUM SODIUM; DOXAZOSIN; FINASTERIDE; INDAPAMIDE; MAGNESIUM CITRATE; MAGNESIUM OXIDE; POTASSIUM DIHYDROGEN PHOSPHATE; SELENIUM; THIAZIDE DIURETIC AGENT;

BLADDER CARCINOMA; HUMAN; NEPHROLITHIASIS; OUTCOMES RESEARCH; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY; TRANSURETHRAL RESECTION; URINARY TRACT DISEASE; URINE FLOW RATE;

EID: 0034332654     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00743-3     Document Type: Article

References (27)

1. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of the AFCAPS/TexCAPS
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
7. Demographic and geographic variability of kidney stones in the United States
8. Incidence of upper urinary tract stones
9. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis
10. Cancer statistics. 1996
11. Intravesical therapy: Does it affect the natural history of superficial bladder cancer?
12. Bladder cancer, 1996
13. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial
14. Chemoprevention trial of selenium and prostate cancer
15. Design of the Prostate Cancer Prevention Trial (PCPT)
16. Design of Physicians' Health Study II - A randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials
17. The management of men with acute urinary retention
18. Trial without catheter following acute retention of urine
19. Acute urinary retention - A urodynamic assessment
20. Sustained-release alfuzosin and trial without catheter after acute urinary retention: A prospective, placebo-controlled trial
21. Long-term follow-up following presentation with first episode of acute urinary retention (abst)
22. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia
23. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study
24. Natural history of prostatism: Risk factors for acute urinary retention
25. Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial (abst)
26. Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice